Oncology: Ranking and Detailed Regulatory Approval Profiles - 157 Cancer Drugs (1985-2016)

  • ID: 3934602
  • Report
  • Region: Global
  • 523 Pages
  • Cancer Research Analytics
1 of 5
Drug Approvals by USFDA, EMA and PMDA Show Detailed Indications, Broader indications and Approval Dates

FEATURED COMPANIES

  • Abbvie
  • Chugai
  • GSK
  • Meda Pharma
  • Norgine Pharma
  • Seattle Genetics
  • MORE

“Oncology: Ranking and detailed regulatory approval profiles - 157 cancer drugs (1985-2016)” is a comprehensive drug ranking and profiling report that ranks cancer drugs based on total approvals and unique approvals received in US, Europe and Japan. It provides the regulatory approval details of each drug for the past 30 years (1985-2016) in both the tabular and (an interesting) infographic formats. Additionally, the basic drug-specific information such as first approvals, breakthrough, orphan designations, black box warnings, etc., is also presented along with negative developments of drugs recalled, discontinued and withdrawn.

We have screened and segmented 157 drugs (from a list of 250 approved cancer drugs) based on the criteria of at least one new or additional approval in the past decade. This report gives detailed information about these drugs and their approval histories from all the three regulatory bodies, namely, the US-based United States Food and Drugs Authority (USFDA), Europe-based European Medicines Agency (EMA) and Japan-based Pharmaceuticals and Medical Devices Agency (PMDA).

The report is divided into two broader sections (Ranking and Drug Profiles) and several sub-sections. We have sequenced 157 drugs into six segments based on total number of approvals: Segment A -  25+ approvals; Segment B - 15 to 24 approvals; Segment C - 10 to 14 approvals; Segment D - 5 to 9 approvals; Segment E - 2 to 4 approvals; Segment F -  only one approval. Similarly, drugs are ranked in various segments based on unique approvals. Each drug in the drug profile section is described in the following three parts: Part 1 - basic information, Part 2 - approval timeline infographic and Part 3 - approval history tables.

Part 1: The basic information section covers:

Trade names: Drugs are often known by different brand names (trade names) in different geographies. For instance, Rituxan is the trade name for Rituximab in the US, whereas it is known as Mabthera in Europe. We have presented each drug’s trade name used in different geographies in our report.

Companies involved in marketing: Drugs are often sold or marketed in different geographies by different companies. For instance, Aranesp is marketed in the US and Europe by Amgen, whereas in Japan it is marketed by Kyowa Hakko Kirin.

Active pharmaceutical ingredient: Active pharmaceutical ingredients (API) are the active ingredients in medications, carried by the excipient. In each case, the drug has an API and it has a trade name, by which it is known in the market. For instance, Revlimid is the brand or trade name, whereas lenalidomide is its API.

Therapy segment: We have classified drugs into five major therapy segments - Targeted, Chemo, Hormone, Vaccines and Adjuvants. For instance, Herceptin is a Targeted Therapy drug whereas Zytiga is a Hormone Therapy drug.

Immuno-oncology: This is a growing area of cancer therapy. We have highlighted whether the drugs classified fall under this category or not. For instance, Opdivo is an immuno-oncology drug.

Class of drug: Various therapy segments are further classified into classes of drugs. Monoclonal antibodies, tyrosine kinase and alkylating agent are examples of classes of drugs. Yervoy is a monoclonal antibody whereas Tarceva is a tyrosine kinase inhibitor.

Designations: Drugs are given designations like “orphan”, “priority review”, “accelerated”, etc., by regulatory authorities, which fast-track their approval process. For instance, Venclexta is an orphan drug (drug developed to treat a rare medical condition) and Erivedge is a “priority review” drug (drug granted expedited review by USFDA in case of treatment of neglected diseases).

First-in-class: In the drug snapshot section, we have mentioned whether a drug is first-in-class or not. Drugs that use a unique and new mechanism of action for treating a medical condition are known as first-in-class drugs. For instance, Avastin is a first-in-class drug as it was the first angiogenesis inhibitor.

Molecule type: Drugs are classified into two categories, small and large, on the basis of their molecular weight; greater than 900 daltons are large molecules and less than 900 daltons are small molecules. Large molecules are also known as biological drugs. Gazyva is a large molecule drug whereas Imbruvica is a small molecule drug. 

Dosage form: We have explained whether the dosage is in the form of vials/injections (injectable) or tablets/capsules (oral). For instance, Tecentriq is an injectable drug whereas Thalomid is an oral tablet.

Route of administration: We have explained whether the drug is taken orally or through the intravenous route. For instance, Empliciti (for multiple myeloma) is taken through the intravenous route.

Black box warning: A black box warning is the strictest warning put in the labeling of prescription drugs or drug products by the USFDA when there is reasonable evidence of an association of a serious hazard with the drug. For instance, Tasigna (a drug for Chronic Myeloid Leukemia) comes with a black box warning “Tasigna has the propensity to elongate part of the heart's rhythm. This is generally not an issue. However, if the patient has a heart condition, or a family history of heart issues, he/she should discuss it with his/her doctor.”

Mechanism of action: The term mechanism of action refers to the specific biochemical interaction through which a drug substance produces its pharmacological effect. A mechanism of action usually includes mention of the specific molecular targets to which the drug binds, such as an enzyme or receptor.

First approved indication in the geographies US, EU and Japan: Many cancer drugs are often approved for more than one indication. We have highlighted the first approved indication of each drug in the various geographies. For instance, Xeloda was first approved for metastatic breast cancer in the US and Japan whereas, in Europe, it was first approved for colorectal cancer.

Note: In this report, we have covered only oncology indications and approvals. Any drug approved for a non-oncology indication in any geography but not approved for oncology indication is marked as “Not Applicable (not yet approved)”. For instance, Vargatef is shown as “N/A (not yet approved)” in US (even though it is approved for a non-oncology indication Idiopathic Pulmonary Fibrosis under the trade name Ofev). Similarly, first approval dates mentioned in the table are also for oncology indications. For any drug that is first approved for a non-oncology indication and later for an oncology indication, we have considered the later date as the first approval date. For instance, for Aranesp, the first approval date is given as 2002 (when it was approved for an oncology indication chemotherapy-induced anaemia) despite the fact that it was approved first for a non-oncology indication anaemia from renal dialysis.

In case of trade names or brand names, we have used oncology brand names and excluded non-oncology brand names. Example: Afinitor is also known as Zortress in the US for treatment of a non-oncology indication, preventing transplant rejection. However, we have used Afinitor and not Zortress in this report. In some cases, brand names for oncology and non-oncology indications are the same. Example: Rituxan is used for oncology as well as rheumatoid arthritis.  

Part 2: The approval timeline infographic
It is a graphical representation of approval history with date of approval, type of approval, indications, designations and lines of treatment.

Part 3: Approval history tables
Drug approvals by USFDA, EMA and PMDA show detailed indications, broader indications, approval dates, in combination with, treatment preference and orphan designation dates. We have highlighted the unique indications in bold. Withdrawn and discontinued approvals are highlighted in red in the infographic and the tables. For all the drugs, we have excluded approvals related to non-oncology and benign tumor indications.

Rationale for ranking
We have ranked drugs based on total number of approvals and unique approvals. For example, if a particular drug is approved in the US, Europe and Japan for one indication, then its total number of approvals are three whereas its unique approval is one (as it is approved for totally one indication). Similarly, if a particular drug is approved for two same indications in the US and Japan and one indication (of those two) in Europe, then its total number of approvals are five whereas its unique approvals are two. The reasoning behind the total approval ranking is that each geography has separate filings, separate clinical trials and indicates separate incremental patient population, which gives separate incremental sales figures. The purpose of unique approval ranking, on the other hand, is to classify drugs based on unique number of indications approved.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie
  • Chugai
  • GSK
  • Meda Pharma
  • Norgine Pharma
  • Seattle Genetics
  • MORE

Methodology

Part I: Ranking section: 157 drugs are ranked on the basis of total approvals and unique approvals received in US, Europe and Japan

Part I (a): Ranking based on total approvals:
Segment A: Drugs with 25+ total approvals
Segment B: Drugs with 15 to 24 approvals
Segment C: Drugs with 10 to 14 approvals
Segment D: Drugs with 5 to 9 approvals
Segment E: Drugs with 2 to 4 approvals
Segment F: Drugs with 1 approval

Part I (b): Ranking based on unique approved indications:

Table including number of unique approved indications, drugs, number of approved broader indications and list of broader indication for 157 drugs
Drugs with 13 unique approved indications
Drugs with 12 unique approved indications
Drugs with 9 unique approved indications
Drugs with 8 unique approved indications
Drugs with 7 unique approved indications
Drugs with 6 unique approved indications
Drugs with 5 unique approved indications
Drugs with 4 unique approved indications
Drugs with 3 unique approved indications
Drugs with 2 unique approved indications
Drugs with 1 unique approved indications

Part II: Drug profile sections:

Drug format:
1. Trade/brand names - US, EU, Japan
2. Companies involved in marketing - US, EU, Japan
3. Designations - Orphan/breakthrough/accelerated/prioriy/fast-track/conditional
4. API
5. Therapy segment - Targeted/chemo/hormone/vaccine/adjuvant
6. Immuno-oncology status - Yes/No
7. Class of drug - Tyrosine kinase, immunomodulator, etc
8. First-in-class status - Yes / No
9. Molecule type - Small / large / vaccines
10. Dosage form
11. Route of administration
12. Black box warning - Yes/No
13. Mechanism of action
14. Total/unique approvals
15. First approved indication in US, EU, Japan
16. Molecular structure
17. Recall, withdrawal, discontinuation details (wherever applicable)

Drug approval timeline - Infographic
Drug approval details - US, EU, Japan
1. Approved indication details
2. Broader indication - Lung, breast cancer, etc
3. Approval date
4. In combination with - Chemotherapeutic agents, etc
5. Treatment preference - First line, second line, third line, etc
6. Orphan designation date

Drugs:
1. Abraxane - protein bound paclitaxel Time range (first approval - last received approval; updated till September 2016): January 2005 to February 2015
2. Abstral, Rapinyl - fentanyl citrat Time range (first approval - last received approval; updated till September 2016): September 2008 to September 2013
3. Adcetris - brentuximab vedotin Time range (first approval - last received approval; updated till September 2016): August 2011 to June 2016
4. Afinitor - everolimus Time range (first approval - last received approval; updated till September 2016): March 2009 to May 2016
5. Akynzeo - netupitant, palonosetron Time range (first approval - last received approval; updated till September 2016): October 2014 to May 2015
6. Alecensa - alectinib Time range (first approval - last received approval; updated till September 2016): July 2014 to December 2015
7. Alimta - pemetrexed Time range (first approval - last received approval; updated till September 2016): February 2004 to October 2012
8. Aloxi - palonosetron Time range (first approval - last received approval; updated till September 2016): July 2003 to February 2015
9. Aranesp, Nesp - darepoetin alfa Time range (first approval - last received approval; updated till September 2016): July 2002 to December 2014
10. Arranon, Atriance - nelarabine Time range (first approval - last received approval; updated till September 2016): October 2005 to October 2007
11. Arzerra - ofatumumab Time range (first approval - last received approval; updated till September 2016): October 2009 to August 2016
12. Avastin - bevacizumab Time range (first approval - last received approval; updated till September 2016): February 2004 to June 2016
13. Beleodaq - belinostat Time range (first approval - last received approval; updated till September 2016): July 2014
14. Blincyto - blinatumomab Time range (first approval - last received approval; updated till September 2016): December 2014 to September 2016
15. Bosulif - bosutinib Time range (first approval - last received approval; updated till September 2016): September 2012 to September 2014
16. Busulfex, Busilvex - busulfan Time range (first approval - last received approval; updated till September 2016): February 1999 to August 2014
17. Campath, MabCampath - alemtuzumab Time range (first approval - last received approval; updated till September 2016): May 2001 to September 2014
18. Camptosar, Campto - irinotecan hydrochlorideTime range (first approval - last received approval; updated till September 2016): 1994 to December 2013
19. Caprelsa - vandetanib Time range (first approval - last received approval; updated till September 2016): April 2011 to September 2015
20. Cervarix - HPV bivalent vaccine Time range (first approval - last received approval; updated till September 2016): September 2007 to July 2016
21. Clolar, Evoltra - clofarabine Time range (first approval - last received approval; updated till September 2016): December 2004 to March 2013
22. Cometriq, Cabometyx - cabozantinib Time range (first approval - last received approval; updated till September 2016): November 2012 to April 2016
23. Cotellic - cobimetinib Time range (first approval - last received approval; updated till September 2016): November 2015
24. Cyramza - ramucirumab Time range (first approval - last received approval; updated till September 2016): April 2014 to June 2016
25. Dacogen - decitabine Time range (first approval - last received approval; updated till September 2016): May 2006 to September 2012
26. Darzalex - daratumumab Time range (first approval - last received approval; updated till September 2016): November 2015 to May 2016
27. Doxil, Caelyx - doxorubicin Time range (first approval - last received approval; updated till September 2016): November 1995 to April 2009
28. Elitek, Fasturtec, Rasuritek - rasburicase Time range (first approval - last received approval; updated till September 2016): February 2001 to October 2009
29. Eloxatin, Elplat - oxaliplatin Time range (first approval - last received approval; updated till September 2016): April 1996 to November 2015
30. Emend, Proemend, Ivemend - aprepitant, fosaprepitant dimeglumine Time range (first approval - last received approval; updated till September 2016): March 2003 to March 2016
31. Empliciti - elotuzumab Time range (first approval - last received approval; updated till September 2016): November 2015 to May 2016
32. Eporatio - epoetin theta Time range (first approval - last received approval; updated till September 2016): October 2010
33. Erbitux - cetuximab Time range (first approval - last received approval; updated till September 2016): February 2004 to April 2015
34. Erivedge - vismodegib Time range (first approval - last received approval; updated till September 2016): January 2012 to July 2013
35. Erwinaze, Erwinase - asparaginase erwinia chrysanthemi Time range (first approval - last received approval; updated till September 2016): July 1985 to November 2011
36. Evista - raloxifene Time range (first approval - last received approval; updated till September 2016): March 2000 to September 2007
37. Evomela - melphalan Time range (first approval - last received approval; updated till September 2016): March 2016
38. Exjade, Jadenu - deferasirox Time range (first approval - last received approval; updated till September 2016): November 2005 to January 2013
39. Farydak - panobinostat Time range (first approval - last received approval; updated till September 2016): February 2015 to August 2015
40. Faslodex - fulvestrant Time range (first approval - last received approval; updated till September 2016): April 2002 to February 2016
41. Femara, Femar - letrozole Time range (first approval - last received approval; updated till September 2016): August 1996 to September 2006
42. Fentora, Effentora, E-fen - fentanyl buccal Time range (first approval - last received approval; updated till September 2016): September 2006 to June 2013
43. Fentos - fentanyl citrate Time range (first approval - last received approval; updated till September 2016): April 2010 to June 2014
44. Firmagon, Gonax - degarelix Time range (first approval - last received approval; updated till September 2016): December 2008 to June 2012
45. Folotyn - pralatrexate Time range (first approval - last received approval; updated till September 2016): September 2009
46. Fragmin - dalteparin Time range (first approval - last received approval; updated till September 2016): May 2007
47. Fusilev - levoleucovorin Time range (first approval - last received approval; updated till September 2016): March 2008 to April 2011
48. Gardasil, Gardasil 9, Silgard - HPV vaccine recombinant Time range (first approval - last received approval; updated till September 2016): June 2006 to December 2015
49. Gazyva, Gazyvaro - obinutuzumab Time range (first approval - last received approval; updated till September 2016): November 2013 to June 2016
50. Gemzar - gemcitabine Time range (first approval - last received approval; updated till September 2016): May 1996 to February 2013
51. Gilotrif, Giotrif - afatinib Time range (first approval - last received approval; updated till September 2016): July 2013 to April 2016
52. Gleevec, Glivec - imatinib Time range (first approval - last received approval; updated till September 2016): May 2001 to June 2013
53. Granix - tbo-filgrastim Time range (first approval - last received approval; updated till September 2016): August 2012
54. Halaven - eribulin Time range (first approval - last received approval; updated till September 2016): November 2010 to May 2016
55. Herceptin - trastuzumab Time range (first approval - last received approval; updated till September 2016): September 1998 to November 2011
56. Hycamtin - topotecan Time range (first approval - last received approval; updated till September 2016): May 1996 to November 2015
57. Ibrance - palbociclib Time range (first approval - last received approval; updated till September 2016): February 2015 to February 2016
58. Iclusig - ponatinib Time range (first approval - last received approval; updated till September 2016): December 2012 to September 2016
59. Imbruvica - ibrutinib Time range (first approval - last received approval; updated till September 2016): November 2013 to May 2016
60. Imlygic - talimogene laherparepvec Time range (first approval - last received approval; updated till September 2016): October 2015 to December 2015
61. Inlyta - axitinib Time range (first approval - last received approval; updated till September 2016): January 2012 to September 2012
62. Iressa - gefitinib Time range (first approval - last received approval; updated till September 2016): July 2002 to July 2015
63. Istodax - romidepsin Time range (first approval - last received approval; updated till September 2016): November 2009 to June 2011
64. Ixempra - ixabepilone Time range (first approval - last received approval; updated till September 2016): October 2007
65. Jevtana - cabazitaxel Time range (first approval - last received approval; updated till September 2016): June 2010 to July 2014
66. Jakafi, Jakavi - ruxolitinib Time range (first approval - last received approval; updated till September 2016): November 2011 to September 2015
67. Kadcyla - ado trastuzumab emtansine Time range (first approval - last received approval; updated till September 2016): February 2013 to November 2013
68. Keytruda - pembrolizumab Time range (first approval - last received approval; updated till September 2016): September 2014 to August 2016
69. Kyprolis - carfilzomib Time range (first approval - last received approval; updated till September 2016): July 2012 to June 2016
70. Lazanda, Pecfent - fentanyl Time range (first approval - last received approval; updated till September 2016): August 2010 to June 2011
71. Lenvima - lenvatinib Time range (first approval - last received approval; updated till September 2016): February 2015 to May 2016
72. Lonquex - lipegfilgrastim Time range (first approval - last received approval; updated till September 2016): July 2013
73. Lonsurf - trifluridine, tipiracil Time range (first approval - last received approval; updated till September 2016): March 2014 to April 2016
74. Lupron depot, Enantone, Lucrin, Leuplin - leuprolide Time range (first approval - last received approval; updated till September 2016): April 1985 to September 2015
75. Lynparza - olaparib Time range (first approval - last received approval; updated till September 2016): December 2014
76. Marqibo - vinCRIStine sulfate Time range (first approval - last received approval; updated till September 2016): August 2012
77. Mekinist - trametinib Time range (first approval - last received approval; updated till September 2016): May 2013 to March 2016
78. Mepact - mifamurtide Time range (first approval - last received approval; updated till September 2016): March 2009
79. Miripla - miriplatin Time range (first approval - last received approval; updated till September 2016): October 2009
80. Mozobil - plerixafor Time range (first approval - last received approval; updated till September 2016): December 2008 to July 2009
81. Neulasta, G-lasta - pegfilgrastim Time range (first approval - last received approval; updated till September 2016): January 2002 to November 2015
82. Neupogen, Gran - filgrastim Time range (first approval - last received approval; updated till September 2016): February 1991 to March 2015
83. Nexavar - sorafenib Time range (first approval - last received approval; updated till September 2016): December 2005 to March 2015
84. Ninlaro - ixazomib Time range (first approval - last received approval; updated till September 2016): November 2015
85. Nplate, Romiplate - romiplostim Time range (first approval - last received approval; updated till September 2016): August 2008 to January 2011
86. Odomzo - sonidegib Time range (first approval - last received approval; updated till September 2016): July 2015 to August 2015
87. Oncaspar - pegaspargase Time range (first approval - last received approval; updated till September 2016): February 1994 to January 2016
88. Onivyde - irinotecan Time range (first approval - last received approval; updated till September 2016): October 2015
89. Onsolis, Breakyl, Painkyl - fentanyl buccal Time range (first approval - last received approval; updated till September 2016): July 2009 to October 2010
90. Opdivo - nivolumab Time range (first approval - last received approval; updated till September 2016): July 2014 to May 2016
91. Perjeta - pertuzumab Time range (first approval - last received approval; updated till September 2016): June 2012 to July 2015
92. Pixuvri - pixantrone Time range (first approval - last received approval; updated till September 2016): May 2012
93. Pomalyst, Imnovid - pomalidomide Time range (first approval - last received approval; updated till September 2016): February 2013 to March 2015
94. Portrazza - necitumumab Time range (first approval - last received approval; updated till September 2016): November 2015 to February 2016
95. Poteligeo - mogamulizumab Time range (first approval - last received approval; updated till September 2016): March 2012 to December 2014
96. Prolia - denosumab Time range (first approval - last received approval; updated till September 2016): May 2010 to September 2011
97. Promacta - eltrombopag Time range (first approval - last received approval; updated till September 2016): November 2008 to January 2016
98. Provenge - sipuleucel-T Time range (first approval - last received approval; updated till September 2016): April 2010 to September 2013
99. Purixan, Xaluprine - mercaptopurine Time range (first approval - last received approval; updated till September 2016): March 2012 to April 2014
100. Removab - catumaxomab Time range (first approval - last received approval; updated till September 2016): April 2009
101. Revlimid - lenalidomide Time range (first approval - last received approval; updated till September 2016): December 2005 to July 2016
102. Rituxan, Mabthera - rituximab Time range (first approval - last received approval; updated till September 2016): November 1997 to May 2015
103. Sensipar, Mimpara, Regpara - cinacalcet Time range (first approval - last received approval; updated till September 2016): March 2004 to February 2014
104. Somatuline - lanreotide Time range (first approval - last received approval; updated till September 2016): May 1995 to April 2015
105. Sprycel - dasatinib Time range (first approval - last received approval; updated till September 2016): June 2006 to June 2011
106. Stivarga - regorafenib Time range (first approval - last received approval; updated till September 2016): September 2012 to July 2014
107. Subsys - fentanyl sublingual Time range (first approval - last received approval; updated till September 2016): January 2012
108. Sustol - granisetron Time range (first approval - last received approval; updated till September 2016): August 2016
109. Sutent - sunitinib Time range (first approval - last received approval; updated till September 2016): January 2006 to August 2012
110. Sylatron, PegIntron - peginterferon alfa-2b Time range (first approval - last received approval; updated till September 2016): March 2011 to May 2015
111. Sylvant - siltuximab Time range (first approval - last received approval; updated till September 2016): April 2014 to May 2014
112. Syndros - dronabinol Time range (first approval - last received approval; updated till September 2016): July 2016
113. Synribo - omacetaxine mepesuccinate Time range (first approval - last received approval; updated till September 2016): October 2012
114. Tafinlar - dabrafenib Time range (first approval - last received approval; updated till September 2016): May 2013 to March 2016
115. Tagrisso - osimertinib Time range (first approval - last received approval; updated till September 2016): November 2015 to March 2016
116. Tarceva - erlotinib Time range (first approval - last received approval; updated till September 2016): November 2004 to June 2013
117. Targretin - bexarotene Time range (first approval - last received approval; updated till September 2016): December 1999 to January 2016
118. Tasigna - nilotinib Time range (first approval - last received approval; updated till September 2016): October 2007 to December 2010
119. Taxotere - docetaxel Time range (first approval - last received approval; updated till September 2016): November 1995 to July 2010
120. Tecentriq - atezolizumab Time range (first approval - last received approval; updated till September 2016): May 2016
121. Temodar, Temodal - temozolomide Time range (first approval - last received approval; updated till September 2016): January 1999 to February 2009
122. Thalomid, Thaled, Thalidomide Celgene - thalidomide Time range (first approval - last received approval; updated till September 2016): May 2006 to October 2008
123. Torisel - temsirolimus Time range (first approval - last received approval; updated till September 2016): May 2007 to July 2010
124. Totect, Savene - dexrazoxane Time range (first approval - last received approval; updated till September 2016): July 2006 to January 2014
125. Treanda, Treakisym, Ribomustine, Levact - bendamustine Time range (first approval - last received approval; updated till September 2016): March 2008 to August 2016
126. Teysuno, TS-1 - tegafur, gimeracil, oteracil Time range (first approval - last received approval; updated till September 2016): January 1999 to March 2011
127. Tykerb, Tyverb - lapatinib Time range (first approval - last received approval; updated till September 2016): March 2007 to November 2015
128. Unituxin - dinutuximab Time range (first approval - last received approval; updated till September 2016): March 2015 to August 2015
129. Valchlor - mechlorethamine Time range (first approval - last received approval; updated till September 2016): August 2013
130. Valstar - valrubicin Time range (first approval - last received approval; updated till September 2016): September 1998 to February 2009
131. Vantas - histrelin Time range (first approval - last received approval; updated till September 2016): October 2004 to July 2007
132. Vargatef - nintedanib Time range (first approval - last received approval; updated till September 2016): November 2014
133. Varubi - rolapitant Time range (first approval - last received approval; updated till September 2016): September 2015
134. Vectibix - panitumumab Time range (first approval - last received approval; updated till September 2016): September 2006 to March 2015
135. Velcade - bortezomib Time range (first approval - last received approval; updated till September 2016): May 2003 to June 2015
136. Venclexta - venetoclax Time range (first approval - last received approval; updated till September 2016): April 2016
137. Vidaza - azacitidne Time range (first approval - last received approval; updated till September 2016): May 2004 to October 2015
138. Vistogard - uridine triacetate Time range (first approval - last received approval; updated till September 2016): December 2015
139. Voraxaze - glucarpidase Time range (first approval - last received approval; updated till September 2016): January 2012
140. Votrient - pazopanib Time range (first approval - last received approval; updated till September 2016): October 2009 to March 2014
141. Xalkori - crizotinib Time range (first approval - last received approval; updated till September 2016): August 2011 to March 2016
142. Xeloda - capecitabine Time range (first approval - last received approval; updated till September 2016): April 1998 to August 2016
143. Xgeva, Ranmark - denosumab Time range (first approval - last received approval; updated till September 2016): November 2010 to December 2014
144. Xofigo - radium Ra 223 dichloride Time range (first approval - last received approval; updated till September 2016): May 2013 to March 2016
145. Xtandi - enzalutamide Time range (first approval - last received approval; updated till September 2016): August 2012 to November 2014
146. Yervoy - ipilumumab Time range (first approval - last received approval; updated till September 2016): March 2011 to May 2016
147. Yondelis - trabectedin Time range (first approval - last received approval; updated till September 2016): September 2007 to October 2015
148. Zaltrap - ziv-aflibercept Time range (first approval - last received approval; updated till September 2016): August 2012 to February 2013
149. Zelboraf - vemurafenib Time range (first approval - last received approval; updated till September 2016): August 2011 to December 2014
150. Zevalin - ibritumomab Time range (first approval - last received approval; updated till September 2016): February 2002 to September 2009
151. Zoladex - goserelin Time range (first approval - last received approval; updated till September 2016): January 1987 to March 2014
152. Zolinza - vorinostat Time range (first approval - last received approval; updated till September 2016): October 2006 to July 2011
153. Zometa - zoledronic Time range (first approval - last received approval; updated till September 2016): October 2000 to April 2006
154. Zuplenz, Setofilm, Ondissolve - ondansetron Time range (first approval - last received approval; updated till September 2016): July 2010 to May 2013
155. Zydelig - idelalisib Time range (first approval - last received approval; updated till September 2016): July 2014 to September 2014
156. Zykadia - ceritinib Time range (first approval - last received approval; updated till September 2016): April 2014 to March 2016
157. Zytiga - abiraterone Time range (first approval - last received approval; updated till September 2016): April 2011 to July 2014

Appendix
Coverage list - API
Coverage list - Brand names
Abbreviations
Disclaimer

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

- Abbvie
- Accredo Speciality Pharmacy
- Amgen
- Ariad
- Astellas
- AstraZeneca
- BMS
- BTG
- Bayer
- BioDelivery Sciences
- Boehringer Ingelheim
- CTI Biopharma
- Celgene
- Chugai
- Clinigen Healthcare
- Daiichi Sankyo
- Depomed
- Eisai
- Eli Lilly
- Endo Pharma
- Exelixis
- Ferring Pharmaceuticals
- GSK
- Gilead Sciences
- Helsinn
- Heron Therapeutics
- Hisamitsu
- Incyte
- Insys
- Ipsen
- J&J
- Jazz Pharma
- KHK
- Kissie pharma
- Meda Pharma
- Merck & Co
- Merck KgaA
- Merrimack Pharmaceuticals
- Midatech Pharma
- Minophagen pharma
- Mundi Pharma
- Mundipharma
- Neovii Biotech GmbH
- Nippon Shinyaku
- Nordic Group BV
- Norgine Pharma
- Nova Laboratories
- Novartis
- Ono
- Otsuka
- Pfizer
- PharmaMar
- R-Pharm
- Rare Disease Therapeutics
- Roche
- SOBI
- Sanofi
- Seattle Genetics
- Sentanyl
- Shire
- Spectrum Pharma
- Sumitomo Dainippon
- Symbio pharma
- TTY Biopharm
- Takeda
- Tesaro
- Teva
- United Therapeutics
- Valeant
- Yakult Honsha

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll